

NIVS Communication 06 June 2023

Dear NIVS Users,


AMENDMENT to NIVS communication sent 05/06/2023. NIVS release date has changed to 14th June 2023

Please disseminate the below communications to all in your organisation who use NIVS

NIVS will be unavailable between 22:00 – 23:00 on 14th June 2023 to allow the following changes to be implemented.

Full Vaccination History

On the evening of 14th June NIVS will be making a change that will present you with a view that provides a patients Full Vaccination history for Flu and COVID-19 vaccination events. NIVS Vaccinators will be presented with additional information (See the below images from Pre-screening)



The page will collapse/expand as required.



Vaccine Decommissioning





NIVS will also be removing the following vaccines from the system. These will no longer be available to Vaccinators on the Add Batch screen or in dropdowns on the Edit Vaccination page.

- Comirnaty 30micrograms/0.3ml dose (Pfizer)
- Vaxzevria 0.5ml dose (AstraZeneca)
- Spikevax 0.1mg/0.5ml dose (Moderna)

Please be advised that the NIVS Team **DOES NOT** send communications via text message. If you ever receive a text message claiming to be from NIVS, **DO NOT** click on any links that are in the text.

Kind regards,

National Immunisation & Vaccination System Support Team

Telephone: 0121 611 0187

Email: nivs@england.nhs.net

Web: http://nivs.ardengemcsu.nhs.uk/home





This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this email, or any disclosure or copying of its content, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Please consider the environment before printing this e-mail.

This email is intended only for use by the named addressee. It may contain confidential and/or privileged information. If you are not the intended recipient, you should contact us/the sender immediately and should not disclose, use or rely on this email. We do not accept any liability arising from a third party taking action, or refraining from taking action, on the basis of information contained in this email. Thank you